AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 81_CD 5Taxation_NNP Profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN ,_, as_IN shown_VBN in_IN the_DT Group_NNP profit_NN and_CC loss_NN account_NN ,_, was_VBD as_IN follows_VBZ :_: 2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD UK_NNP 1,123_CD 879_CD 741_CD Overseas_JJ 3,962_CD 3,323_CD 3,296_CD 5,085_CD 4,202_CD 4,037_CD Taxes_NNS on_IN profit_NN on_IN ordinary_JJ activities_NNS were_VBD as_IN follows_VBZ :_: UK_NNP taxation_NN Corporation_NNP tax_NN 379 142 165_CD Double_RB taxation_NN relief_NN 22_CD 23_CD 29_CD Adjustments_NNS in_IN respect_NN of_IN prior_JJ periods_NNS 178_CD Deferred_JJ taxation_NN 45_CD 102 24 224 221_CD 160_CD Overseas_JJ taxation_NN Overseas_JJ taxes_NNS 992 783 929_CD Adjustments_NNS in_IN respect_NN of_IN prior_JJ periods_NNS 7_CD 26_CD 51_CD Deferred_JJ taxation_NN 31 113 139_CD 1,030_CD 922_CD 1,017_CD Tax_NNP on_IN profit_NN on_IN ordinary_JJ activities_NNS 1,254_CD 1,143_CD 1,177_CD UK_NNP and_CC overseas_JJ taxation_NN has_VBZ been_VBN provided_VBN at_IN current_JJ rates_NNS on_IN the_DT profits_NNS earned_VBN for_IN the_DT periods_NNS covered_VBN by_IN the_DT Group_NNP Financial_NNP Statements_NNP ._.
The_DT prior_JJ period_NN adjustment_NN in_IN respect_NN of_IN UK_NNP taxation_NN relates_VBZ to_TO the_DT settlement_NN of_IN a_DT number_NN of_IN tax_NN issues_NNS covering_VBG several_JJ accounting_NN periods_NNS including_VBG merger_NN costs_NNS ,_, divestment_JJ provisions_NNS and_CC fixed_VBN asset_NN valuations_NNS ._.
Deferred_JJ tax_NN profit_NN and_CC loss_NN account_VBP amounts_NNS arise_VB principally_RB in_IN respect_NN of_IN the_DT origination_NN and_CC reversal_NN of_IN timing_NN differences_NNS ._.
To_TO the_DT extent_NN that_IN dividends_NNS remitted_VBN from_IN overseas_JJ subsidiaries_NNS ,_, joint_JJ ventures_NNS and_CC associates_NNS are_VBP expected_VBN to_TO result_VB in_IN additional_JJ taxes_NNS ,_, appropriate_JJ amounts_NNS have_VBP been_VBN provided_VBN for_IN ._.
No_DT deferred_JJ tax_NN has_VBZ been_VBN provided_VBN for_IN unremitted_JJ earnings_NNS of_IN Group_NNP companies_NNS overseas_RB as_IN these_DT are_VBP ,_, in_IN the_DT main_JJ ,_, considered_VBN permanently_RB employed_VBN in_IN the_DT businesses_NNS of_IN these_DT companies_NNS and_CC ,_, in_IN the_DT case_NN of_IN joint_JJ ventures_NNS and_CC associates_NNS ,_, the_DT taxes_NNS would_MD not_RB be_VB material_NN ._.
Cumulative_JJ unremitted_JJ earnings_NNS of_IN overseas_JJ subsidiaries_NNS and_CC related_VBN undertakings_NNS totalled_VBD approximately_RB $_$ 11,073_CD m_NN at_IN 31_CD December_NNP 2004_CD 2003_CD $_$ 9,381_CD m._FW Unremitted_JJ earnings_NNS may_MD be_VB liable_JJ to_TO overseas_JJ taxes_NNS and_CC or_CC UK_NNP taxation_NN after_IN allowing_VBG for_IN double_JJ taxation_NN relief_NN if_IN they_PRP were_VBD to_TO be_VB distributed_VBN as_IN dividends_NNS ._.
Exceptional_JJ items_NNS included_VBN in_IN tax_NN on_IN profit_NN on_IN ordinary_JJ activities_NNS :_: 2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD Tax_NNP credit_NN on_IN exceptional_JJ items_NNS 67_CD Includes_VBZ deferred_JJ tax_NN relief_NN of_IN $_$ 9m_CD 2003_CD $_$ nil_CD ,_, 2002_CD $_$ nil_JJ ._.
The_DT tax_NN credit_NN on_IN exceptional_JJ items_NNS includes_VBZ an_DT amount_NN of_IN $_$ 58m_CD arising_VBG from_IN an_DT agreement_NN with_IN the_DT US_NNP tax_NN authority_NN to_TO allow_VB $_$ 170m_CD of_IN the_DT Zoladex_NNP settlement_NN originally_RB accrued_VBN in_IN 2002_CD and_CC paid_VBN in_IN 2003_CD as_IN deductible_JJ for_IN tax_NN ._.
There_EX is_VBZ also_RB a_DT tax_NN credit_NN of_IN $_$ 9m_CD arising_VBG on_IN costs_NNS associated_VBN with_IN the_DT disposal_NN of_IN Advanta_NNP BV_NNP ._.
Statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS In_IN certain_JJ circumstances_NNS ,_, tax_NN charges_NNS or_CC credits_NNS on_IN currency_NN translation_NN differences_NNS on_IN foreign_JJ currency_NN borrowings_NNS are_VBP taken_VBN to_TO reserves_NNS via_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
The_DT tax_NN charge_NN on_IN such_JJ currency_NN translation_NN differences_NNS amounted_VBD to_TO $_$ nil_CD in_IN 2004_CD 2003_CD $_$ nil_CD ,_, 2002_CD $_$ 2m_CD and_CC has_VBZ been_VBN reported_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
The_DT tax_NN credit_NN on_IN other_JJ consolidation_NN exchange_NN adjustments_NNS taken_VBN to_TO reserves_NNS amounted_VBD to_TO $_$ 22m_CD in_IN 2004_CD 2003_CD $_$ 66m_CD ,_, 2002_CD $_$ 135m_CD ._.
The_DT movement_NN in_IN reserves_NNS via_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS also_RB includes_VBZ a_DT tax_NN credit_NN of_IN $_$ 357m_CD ,_, arising_VBG from_IN agreement_NN with_IN the_DT tax_NN authorities_NNS to_TO allow_VB a_DT proportion_NN of_IN certain_JJ foreign_JJ exchange_NN losses_NNS arising_VBG on_IN intra-group_JJ balances_NNS in_IN 2000_CD ._.
Factors_NNS affecting_VBG future_JJ tax_NN charges_NNS As_IN a_DT group_NN involved_VBN in_IN worldwide_JJ operations_NNS ,_, AstraZeneca_NNP is_VBZ subject_JJ to_TO several_JJ factors_NNS that_WDT may_MD affect_VB future_JJ tax_NN charges_NNS ,_, principally_RB the_DT levels_NNS and_CC mix_NN of_IN profitability_NN in_IN different_JJ jurisdictions_NNS ,_, transfer_NN pricing_NN policies_NNS and_CC tax_NN levels_NNS imposed_VBN ._.
A_DT number_NN of_IN material_NN items_NNS currently_RB under_IN audit_NN and_CC negotiation_NN are_VBP set_VBN out_RP in_IN detail_NN in_IN Note_NN 30_CD ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 82_CD Form_NN 20-F_JJ Information_NN 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 5Taxation_JJ continued_VBN Tax_NNP reconciliation_NN to_TO UK_NNP statutory_JJ rate_NN The_DT table_NN shown_VBN below_IN reconciles_NNS the_DT UK_NNP statutory_JJ tax_NN charge_NN to_TO the_DT Groups_NNS current_JJ tax_NN charge_NN on_IN profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN ._.
2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD Profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 5,085_CD 4,202_CD 4,037_CD Notional_NNP taxation_NN charge_NN at_IN UK_NNP corporation_NN tax_NN rate_NN of_IN 30_CD %_NN 30_CD %_NN for_IN 2003_CD ,_, 30_CD %_NN for_IN 2002_CD 1,525_CD 1,261_CD 1,211_CD Differences_NNS in_IN effective_JJ overseas_JJ tax_NN rates_NNS 55 159 141_CD Capital_NNP allowances_NNS tax_NN reliefs_NNS in_IN excess_NN of_IN depreciation_NN 33 291 291_CD Untaxed_JJ reserves_NNS 186_CD 51_CD 75_CD Other_JJ timing_NN differences_NNS 145_CD 168_CD 35_CD Items_NNS not_RB deductible_JJ for_IN tax_NN purposes_NNS 38_CD 80_CD 49_CD Items_NNS not_RB chargeable_JJ for_IN tax_NN purposes_NNS 71_CD 88_CD 110_CD Adjustments_NNS in_IN respect_NN of_IN prior_JJ periods_NNS 171_CD 26_CD 51_CD Exceptional_JJ items_NNS 124_CD 105_CD Current_JJ tax_NN charge_NN for_IN the_DT year_NN 1,178_CD 928_CD 1,014_CD Balance_NN sheet_NN 2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD Deferred_VBN taxation_NN liability_NN asset_NN movement_NN At_IN beginning_NN of_IN year_NN 693 359 212_CD Profit_NN and_CC loss_NN account_NN 76 215 163_CD Statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS 78_CD 155_CD Disposal_NN of_IN subsidiary_NN undertakings_NNS 4_CD 13_CD Exchange_NNP 112 132 139_CD At_IN end_NN of_IN year_NN 799 693 359_CD Debtors_NNS amount_NN due_JJ within_IN one_CD year_NN Note_NN 13 623 732 625_CD Debtors_NNS amount_NN due_JJ after_IN more_JJR than_IN one_CD year_NN Note_NN 13 159 165 226_CD Provisions_NNS Note_VBP 19_CD 1,581_CD 1,590_CD 1,210_CD 799 693 359_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 83_CD 5Taxation_NN continued_VBD Deferred_JJ taxation_NN The_DT amounts_NNS of_IN deferred_VBN taxation_NN accounted_VBD for_IN in_IN the_DT Group_NNP balance_NN sheet_NN ,_, before_IN netting_VBG off_IN of_IN balances_NNS within_IN countries_NNS ,_, comprised_VBD the_DT following_JJ deferred_JJ tax_NN liabilities_NNS and_CC assets_NNS :_: 2004_CD 2003_CD $_$ m_CD $_$ m_CD Deferred_VBN tax_NN liabilities_NNS UK_NNP fixed_VBN assets_NNS 609_CD 501_CD Non-UK_JJ fixed_JJ assets_NNS 767_CD 735_CD Interest_NN accruals_VBZ 28_CD 18_CD Untaxed_JJ reserves_NNS 360_CD 137_CD Pension_NN and_CC post-retirement_NN benefits_NNS 194_CD 86_CD Other_JJ 89_CD 175_CD 2,047_CD 1,652_CD Deferred_JJ tax_NN assets_NNS Intercompany_NNP inventory_NN transfers_NNS 643_CD 527_CD Non-UK_JJ fixed_JJ assets_NNS 44_CD 28_CD Accrued_VBN expenses_NNS 384_CD 238_CD Pension_NN and_CC post-retirement_NN benefits_NNS 94_CD 55_CD Other_JJ 83_CD 111_CD 1,248_CD 959_CD Deferred_JJ tax_NN liability_NN net_JJ 799_CD 693_CD No_DT provision_NN has_VBZ been_VBN made_VBN ,_, in_IN accordance_NN with_IN FRS_NNP 19_CD ,_, for_IN rolled_VBN over_IN gains_NNS amounting_VBG to_TO $_$ 106m_CD 2003_CD $_$ 131m_CD ,_, 2002_CD $_$ 118m_CD ._.
